NC
ITOS

NinePointTwo Capital’s iTeos Therapeutics ITOS Stock Holding History

NinePointTwo Capital’s Portfolio ITOS Stock Details ITOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		$193K Hold
17,677
– – 0.08% 228
2023
Q3 		$193K Hold
17,677
– – 0.08% 220
2023
Q2 		$234K Sell
17,677
-1,833
-9% -$26.1K 0.09% 163
2023
Q1 		$265K Buy
+19,510
New +$350K 0.1% 89
2022
Q4 		– Sell
-15,773
Closed -$300K – 222
2022
Q3 		$300K Hold
15,773
– – 0.12% 98
2022
Q2 		$324K Buy
15,773
+5,095
+48% +$121K 0.11% 116
2022
Q1 		$343K Buy
+10,678
New +$388K 0.09% 98

Other funds holding ITOS

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

NinePointTwo Capital's ITOS Position: Q4 2023 in Review

NinePointTwo Capital held its iTeos Therapeutics (ITOS) position steady in Q4 2023 at 17,677 shares worth $193K. The position accounts for 0.08% of the portfolio, ranked #228.

NinePointTwo Capital first reported a position in ITOS in Q1 2022 and has held it in 7 quarters since. The position peaked at $343K in Q1 2022. 137 funds tracked by Wall St. Rank hold ITOS as of Q4 2023.

  • NinePointTwo Capital held 17,677 shares of iTeos Therapeutics worth $193K as of Q4 2023.
  • NinePointTwo Capital left its iTeos Therapeutics share count unchanged in Q4 2023.
  • iTeos Therapeutics made up 0.08% of NinePointTwo Capital's portfolio in Q4 2023, its #228 holding.
  • NinePointTwo Capital first reported a position in iTeos Therapeutics in Q1 2022 and has held it in 7 quarters since.
  • NinePointTwo Capital's iTeos Therapeutics position peaked at $343K in Q1 2022.
  • 137 funds tracked by Wall St. Rank held iTeos Therapeutics as of Q4 2023.

Based on NinePointTwo Capital's 13F filing for Q4 2023, filed 14 Feb 2024.